Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.

Goldberg AA, Joung KB, Mansuri A, Kang Y, Echavarria R, Nikolajev L, Sun Y, Yu JJ, Laporte SA, Schwertani A, Kristof AS.

Oncotarget. 2016 Sep 20;7(38):61152-61165. doi: 10.18632/oncotarget.10748.

2.

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88. Epub 2007 Dec 19.

PMID:
18094073
3.

Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.

Sun Y, Zhang E, Lao T, Pereira AM, Li C, Xiong L, Morrison T, Haley KJ, Zhou X, Yu JJ.

Horm Cancer. 2014 Oct;5(5):284-98. doi: 10.1007/s12672-014-0192-z. Epub 2014 Jul 29.

4.

Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.

Li C, Zhang E, Sun Y, Lee PS, Zhan Y, Guo Y, Osorio JC, Rosas IO, Xu KF, Kwiatkowski DJ, Yu JJ.

PLoS One. 2014 Oct 27;9(10):e104809. doi: 10.1371/journal.pone.0104809. eCollection 2014.

5.

Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.

Stepanova V, Dergilev KV, Holman KR, Parfyonova YV, Tsokolaeva ZI, Teter M, Atochina-Vasserman EN, Volgina A, Zaitsev SV, Lewis SP, Zabozlaev FG, Obraztsova K, Krymskaya VP, Cines DB.

J Biol Chem. 2017 Dec 15;292(50):20528-20543. doi: 10.1074/jbc.M117.799593. Epub 2017 Sep 27.

6.

Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.

Wang F, Chen X, Li C, Sun Q, Chen Y, Wang Y, Peng H, Liu Z, Chen R, Liu K, Yan H, Ye BH, Kwiatkowski DJ, Zhang H.

Oncogene. 2014 Aug 21;33(34):4352-8. doi: 10.1038/onc.2013.401. Epub 2013 Sep 30.

PMID:
24077282
7.

TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis.

Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J.

Cancer Res. 2007 Nov 1;67(21):10573-81.

8.

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.

Am J Respir Cell Mol Biol. 2014 Dec;51(6):738-49. doi: 10.1165/rcmb.2014-0033OC.

9.

Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Li C, Zhou X, Sun Y, Zhang E, Mancini JD, Parkhitko A, Morrison TA, Silverman EK, Henske EP, Yu JJ.

Am J Respir Cell Mol Biol. 2013 Jul;49(1):135-42. doi: 10.1165/rcmb.2012-0476OC.

10.

TSC2 modulates cell adhesion and migration via integrin-α1β1.

Moir LM, Black JL, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2012 Oct 15;303(8):L703-10. doi: 10.1152/ajplung.00414.2011. Epub 2012 Aug 24.

11.

TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.

Lesma E, Ancona S, Sirchia SM, Orpianesi E, Grande V, Colapietro P, Chiaramonte E, Di Giulio AM, Gorio A.

J Cell Mol Med. 2014 May;18(5):766-79. doi: 10.1111/jcmm.12237. Epub 2014 Mar 7.

12.

Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Kristof AS, You Z, Han YS, Giaid A.

Peptides. 2010 Aug;31(8):1511-6. doi: 10.1016/j.peptides.2010.04.017. Epub 2010 Apr 28.

13.

Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.

Prizant H, Taya M, Lerman I, Light A, Sen A, Mitra S, Foster TH, Hammes SR.

Endocr Relat Cancer. 2016 Apr;23(4):265-80. doi: 10.1530/ERC-15-0505. Epub 2016 Feb 15.

14.

Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.

Makovski V, Haklai R, Kloog Y.

Int J Cancer. 2012 Mar 15;130(6):1420-9. doi: 10.1002/ijc.26139. Epub 2011 Aug 1.

15.

Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.

Atochina-Vasserman EN, Abramova E, James ML, Rue R, Liu AY, Ersumo NT, Guo CJ, Gow AJ, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54. doi: 10.1152/ajplung.00262.2015. Epub 2015 Oct 2.

16.

Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Steagall WK, Pacheco-Rodriguez G, Glasgow CG, Ikeda Y, Lin JP, Zheng G, Moss J.

Am J Pathol. 2013 Sep;183(3):938-50. doi: 10.1016/j.ajpath.2013.05.024. Epub 2013 Jul 16.

17.

Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Julian LM, Delaney SP, Wang Y, Goldberg AA, Doré C, Yockell-Lelièvre J, Tam RY, Giannikou K, McMurray F, Shoichet MS, Harper ME, Henske EP, Kwiatkowski DJ, Darling TN, Moss J, Kristof AS, Stanford WL.

Cancer Res. 2017 Oct 15;77(20):5491-5502. doi: 10.1158/0008-5472.CAN-17-0925. Epub 2017 Aug 22.

18.

SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.

Tyryshkin A, Bhattacharya A, Eissa NT.

Cancer Res. 2014 Apr 1;74(7):1996-2005. doi: 10.1158/0008-5472.CAN-13-1256.

19.

Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.

Ng HY, Oliver BG, Burgess JK, Krymskaya VP, Black JL, Moir LM.

J Cell Mol Med. 2015 Nov;19(11):2633-46. doi: 10.1111/jcmm.12593. Epub 2015 Aug 18.

Supplemental Content

Support Center